Can Pre-Surgery hormone cocktail boost erection recovery in prostate cancer?
NCT ID NCT02949284
First seen Jun 24, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This phase 2 trial tests whether giving hormone therapy before prostate surgery helps men with high-risk prostate cancer recover erectile function better. About 90 men will receive either apalutamide alone or a combination of apalutamide, abiraterone, GnRH agonist, and prednisone before nerve-sparing prostate removal. The goal is to see if these drugs shrink tumors and improve post-surgery potency compared to surgery alone.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
apalutamide, abiraterone acetate, GnRH agonist, prednisone
What this could lead to
If successful, this approach could help men with high-risk prostate cancer recover erectile function better after surgery, potentially improving quality of life.
What could go wrong
This is a small, early-phase trial (90 participants) testing combinations of drugs before surgery. Results may not apply to all patients, and side effects from hormone therapy can be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE II PROSTATE ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08903, United States
-
Yale Cancer Center
New Haven, Connecticut, 06519, United States